Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
Barbe R, Belkouchi Y, Menu Y, Cohen R, David C, Kind M, Harguem S, Dawi L, Hadchiti J, Selhane F, Billet N, Ammari S, Bertin A, Lawrance L, Cervantes B, Hollebecque A, Balleyguier C, Cournede PH, Talbot H, Lassau N, Andre T. Barbe R, et al. Among authors: kind m. Eur J Cancer. 2024 May;202:114020. doi: 10.1016/j.ejca.2024.114020. Epub 2024 Mar 16. Eur J Cancer. 2024. PMID: 38502988
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Toulmonde M, Guegan JP, Spalato-Ceruso M, Peyraud F, Kind M, Vanhersecke L, Le Loarer F, Perret R, Cantarel C, Bellera C, Bessede A, Italiano A. Toulmonde M, et al. Among authors: kind m. Mol Cancer. 2024 Feb 20;23(1):38. doi: 10.1186/s12943-024-01946-8. Mol Cancer. 2024. PMID: 38378555 Free PMC article. Clinical Trial.
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Sun CM, Toulmonde M, Spalato-Ceruso M, Peyraud F, Bessede A, Kind M, Cousin S, Buy X, Palussiere J, Bougouin A, Sautès-Fridman C, Fridman HW, Pulido M, Italiano A. Sun CM, et al. Among authors: kind m. Mol Cancer. 2024 Feb 19;23(1):37. doi: 10.1186/s12943-024-01942-y. Mol Cancer. 2024. PMID: 38374062 Free PMC article.
Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial.
Bonvalot S, Cozic N, Le Cesne A, Blay JY, Penel N, Fau M, Chevreau C, Anract P, Waast D, Laurence V, Watson S, Duffaud F, Gouin F, Taieb S, Kind M, Lam L. Bonvalot S, et al. Among authors: kind m. Ann Surg Oncol. 2023 Dec;30(13):8653-8659. doi: 10.1245/s10434-023-14341-2. Epub 2023 Sep 30. Ann Surg Oncol. 2023. PMID: 37777684 Clinical Trial.
Imaging presentation of extraskeletal osteosarcomas on CT and MRI and correlation with patients outcome: A two-center retrospective study of 54 patients.
Crombé A, Spinnato P, Righi A, Leopardi MP, Carpenzano M, Izzo F, Parmeggiani A, Linck PA, Perret R, Cesari M, Longhi A, Miceli M, Kind M, Bianchi G. Crombé A, et al. Among authors: kind m. Diagn Interv Imaging. 2023 Jun;104(6):297-306. doi: 10.1016/j.diii.2023.01.009. Epub 2023 Feb 21. Diagn Interv Imaging. 2023. PMID: 36813659
Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy.
Belkouchi Y, Talbot H, Lassau N, Lawrance L, Farhane S, Feki-Mkaouar R, Hadchiti J, Dawi L, Vibert J, Cournède PH, Cousteix C, Mazza C, Kind M, Italiano A, Marabelle A, Ammari S, Champiat S. Belkouchi Y, et al. Among authors: kind m. Clin Cancer Res. 2023 Apr 14;29(8):1528-1534. doi: 10.1158/1078-0432.CCR-22-0890. Clin Cancer Res. 2023. PMID: 36719966
174 results